checkAd

    Simavita Limited  384  0 Kommentare Cleansing Notice Under Section 708A the Corporations Act 2001 (Cth)

    SYDNEY, AUSTRALIA--(Marketwired - May 22, 2015) - Simavita Limited ("Simavita" or the "Company") (TSX VENTURE:SV)(ASX:SVA) advises that it has allotted a total of 85,555 CDIs in the Company to parties associated with two Directors (the "Placement"). Approval for the issue of such CDIs was received at the Special Meeting held on May 21, 2015. The issue of the CDIs, at the issue price of AUD$0.45 per CDI, raised a total of AUD$38,500 for the Company.

    The proceeds from the issuance of CDIs will be used to accelerate the roll-out of Simavita's current technologies in the US and European markets, appoint further distributors to roll-out SIM in Europe, for continued product innovation and general working capital purposes.

    All CDIs issued pursuant to the Placement are to be fully tradeable and listed on the Australian Securities Exchange (the "ASX"). Quotation of the CDIs issued pursuant to the Placement is expected to occur on the ASX on or about May 25, 2015. The issuance of CDIs is subject to TSX Venture Exchange acceptance of requisite regulatory filings.

    The Company gives this Notice in accordance with section 708A(5)(e) of the Corporations Act 2001 (Cth) (the "Corporations Act").

    The above CDIs were issued without disclosure to investors under Part 6D.2 of the Corporations Act.

    As at the date of this Notice, the Company has complied with:

    • the provision of Chapter 2M of the Corporations Act as they apply to the Company; and
    • section 674 of the Corporations Act.

    As at the date of this Notice, there is no excluded information for the purposes of section 708(7) and section 708(8) of the Corporations Act.

    For further information, please check our website (www.simavita.com).

    About Simavita

    Simavita is a medical device company that has developed an innovative, world first solution for the management of urinary incontinence, with a focus on the elderly. The first product is the SIM platform technology which is an instrumented incontinence assessment application that provides evidence-based incontinence management care plans to the residential aged care market.

    Seite 1 von 3



    Verfasst von Marketwired
    Simavita Limited Cleansing Notice Under Section 708A the Corporations Act 2001 (Cth) SYDNEY, AUSTRALIA--(Marketwired - May 22, 2015) - Simavita Limited ("Simavita" or the "Company") (TSX VENTURE:SV)(ASX:SVA) advises that it has allotted a total of 85,555 CDIs in the Company to parties associated with two Directors (the "Placement"). …

    Schreibe Deinen Kommentar

    Disclaimer